Premium
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Zymeworks BC Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of different... Zymeworks BC Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. Show more
Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers PR Newswire DUBLIN and VANCOUVER, BC...
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming...
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma PR...
Provides updated key priorities and focus on enterprise value framework Closing of Jazz Pharmaceuticals (Jazz) collaboration in fourth quarter completes financial transformation initiatives...
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in an upcoming investor...
Zanidatamab as monotherapy produced a confirmed objective response rate (cORR) of 41.3% and median duration of response of 12.9 months in patients with previously treated HER2-amplified and...
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the upcoming presentation of mature Phase 2 data evaluating...
Results show overall confirmed objective response rate (cORR) of 33%, disease control rate (DCR) of 92%, and median progression-free survival (mPFS) of 9.6 months Data support further...
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced today that it has elected to transfer its stock exchange listing from...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
